CG Oncology
- Founded: 2010
- Location: Irvine, CA
- Employee range: 11 - 50
- Clinical stage: Clin3
- Therapy area: Bladder cancer
- Drug types: ONC
- Lead product: GC0070
- Product link: https://cgoncology.com/pipeline/
- Funding: $105M Aug 2023; $120M E Nov 2022; $47M D Dec 2020; $22M C Mar 2019
- Investors: ORI Capital, Longitude Capital, Decheng Capital, RA Capital Management, Acorn Bioventures, Malin Corporation, Ally Bridge Group, Sirona Capital, Foresite Capital, TCGX
cgoncology.com linkedin.com job board
Short description:
Oncolytic Virus
Drug notes:
Also combo Clin2 bladder cancer, combo Clin1 bladder cancer
Long description:
CG Oncology is developing oncolytic immunotherapies to treat patients with advanced bladder cancer. Bladder cancer is the 4th most common form of cancer in men in the US. To address this CG is genetically engineering oncolytic immunotherapies. The therapy has a dual mechanism of action: first, the therapy infects and replicates inside tumor cells causing cell lysis. Secondly, the rupturing of cancer cells releases tumor-derived antigens that stimulates a systemic anti-tumor immune response. CG has 3 active clinical programs with their lead candidate, CG0070, showing remarkable efficacy in bladder cancer patients in their clinical trials.
Jobs:
© 2023 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com